Cargando…

Therapeutic Effects of Retinoic Acid in Lipopolysaccharide-Induced Cardiac Dysfunction: Network Pharmacology and Experimental Validation

PURPOSE: Sepsis, which is deemed as a systemic inflammation reaction syndrome in the face of infectious stimuli, is the primary cause of death in ICUs. Sepsis-induced cardiomyopathy (SIC) may derive from systemic inflammation reaction and oxidative stress. Retinoic acid (RA) is recognized by its ben...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xi, Kong, Chang, Liu, Pan, Zhou, Baofeng, Geng, Wujun, Tang, Hongli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467448/
https://www.ncbi.nlm.nih.gov/pubmed/36105385
http://dx.doi.org/10.2147/JIR.S358374
_version_ 1784788197069291520
author Wang, Xi
Kong, Chang
Liu, Pan
Zhou, Baofeng
Geng, Wujun
Tang, Hongli
author_facet Wang, Xi
Kong, Chang
Liu, Pan
Zhou, Baofeng
Geng, Wujun
Tang, Hongli
author_sort Wang, Xi
collection PubMed
description PURPOSE: Sepsis, which is deemed as a systemic inflammation reaction syndrome in the face of infectious stimuli, is the primary cause of death in ICUs. Sepsis-induced cardiomyopathy (SIC) may derive from systemic inflammation reaction and oxidative stress. Retinoic acid (RA) is recognized by its beneficial roles in terms of the immunoresponse to infections and antioxygen actions. However, the treatment efficacy and potential causal links of RA in SIC are still elusive. METHODS: By virtue of the STITCH database, we identified the targets of RA. Differentially expressed genes in SIC were acquired from the GEO database. The PPI network of intersected targets was established. GO and KEGG pathway enrichment analysis was completed. Hub genes were analyzed by cytoHubba plug-in. In the process of experimental validation, a mouse sepsis model was established by lipopolysaccharide (LPS), and the treated mice were intraperitoneally injected with RA or Dexamethasone (DEX) 60 min prior to LPS injections. Survival conditions, cardiac functions and antioxidant levels of the mice were assessed. Cardiac inflammation and injury were detected by HE and TUNEL. The levels of key genes and signal pathway expression were analyzed by RT-PCR and Western blot. RESULTS: PPARA, ITGAM, VCAM-1, IGF-1 and IL-6 were identified as key therapeutic targets of RA by network pharmacology. PI3K-Akt signaling pathway is the main regulatory pathway of RA. In vivo researches unraveled that RA can improve the survival rate and cardiac function of LPS-treated mice, inhibit inflammatory factors and myocardial injury, and regulate the expression of key therapeutic targets and key pathways, which is PI3K-Akt signaling pathway. CONCLUSION: Network pharmacological method offers a predicative strategy to explore the treatment efficacy and causal links of RA in endotoxemic myocarditis. Through experimental verification, we discover that RA can reduce lipopolysaccharide-induced cardiac dysfunction by regulating the PI3K-Akt signaling pathway and key genes.
format Online
Article
Text
id pubmed-9467448
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-94674482022-09-13 Therapeutic Effects of Retinoic Acid in Lipopolysaccharide-Induced Cardiac Dysfunction: Network Pharmacology and Experimental Validation Wang, Xi Kong, Chang Liu, Pan Zhou, Baofeng Geng, Wujun Tang, Hongli J Inflamm Res Original Research PURPOSE: Sepsis, which is deemed as a systemic inflammation reaction syndrome in the face of infectious stimuli, is the primary cause of death in ICUs. Sepsis-induced cardiomyopathy (SIC) may derive from systemic inflammation reaction and oxidative stress. Retinoic acid (RA) is recognized by its beneficial roles in terms of the immunoresponse to infections and antioxygen actions. However, the treatment efficacy and potential causal links of RA in SIC are still elusive. METHODS: By virtue of the STITCH database, we identified the targets of RA. Differentially expressed genes in SIC were acquired from the GEO database. The PPI network of intersected targets was established. GO and KEGG pathway enrichment analysis was completed. Hub genes were analyzed by cytoHubba plug-in. In the process of experimental validation, a mouse sepsis model was established by lipopolysaccharide (LPS), and the treated mice were intraperitoneally injected with RA or Dexamethasone (DEX) 60 min prior to LPS injections. Survival conditions, cardiac functions and antioxidant levels of the mice were assessed. Cardiac inflammation and injury were detected by HE and TUNEL. The levels of key genes and signal pathway expression were analyzed by RT-PCR and Western blot. RESULTS: PPARA, ITGAM, VCAM-1, IGF-1 and IL-6 were identified as key therapeutic targets of RA by network pharmacology. PI3K-Akt signaling pathway is the main regulatory pathway of RA. In vivo researches unraveled that RA can improve the survival rate and cardiac function of LPS-treated mice, inhibit inflammatory factors and myocardial injury, and regulate the expression of key therapeutic targets and key pathways, which is PI3K-Akt signaling pathway. CONCLUSION: Network pharmacological method offers a predicative strategy to explore the treatment efficacy and causal links of RA in endotoxemic myocarditis. Through experimental verification, we discover that RA can reduce lipopolysaccharide-induced cardiac dysfunction by regulating the PI3K-Akt signaling pathway and key genes. Dove 2022-08-30 /pmc/articles/PMC9467448/ /pubmed/36105385 http://dx.doi.org/10.2147/JIR.S358374 Text en © 2022 Wang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Wang, Xi
Kong, Chang
Liu, Pan
Zhou, Baofeng
Geng, Wujun
Tang, Hongli
Therapeutic Effects of Retinoic Acid in Lipopolysaccharide-Induced Cardiac Dysfunction: Network Pharmacology and Experimental Validation
title Therapeutic Effects of Retinoic Acid in Lipopolysaccharide-Induced Cardiac Dysfunction: Network Pharmacology and Experimental Validation
title_full Therapeutic Effects of Retinoic Acid in Lipopolysaccharide-Induced Cardiac Dysfunction: Network Pharmacology and Experimental Validation
title_fullStr Therapeutic Effects of Retinoic Acid in Lipopolysaccharide-Induced Cardiac Dysfunction: Network Pharmacology and Experimental Validation
title_full_unstemmed Therapeutic Effects of Retinoic Acid in Lipopolysaccharide-Induced Cardiac Dysfunction: Network Pharmacology and Experimental Validation
title_short Therapeutic Effects of Retinoic Acid in Lipopolysaccharide-Induced Cardiac Dysfunction: Network Pharmacology and Experimental Validation
title_sort therapeutic effects of retinoic acid in lipopolysaccharide-induced cardiac dysfunction: network pharmacology and experimental validation
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467448/
https://www.ncbi.nlm.nih.gov/pubmed/36105385
http://dx.doi.org/10.2147/JIR.S358374
work_keys_str_mv AT wangxi therapeuticeffectsofretinoicacidinlipopolysaccharideinducedcardiacdysfunctionnetworkpharmacologyandexperimentalvalidation
AT kongchang therapeuticeffectsofretinoicacidinlipopolysaccharideinducedcardiacdysfunctionnetworkpharmacologyandexperimentalvalidation
AT liupan therapeuticeffectsofretinoicacidinlipopolysaccharideinducedcardiacdysfunctionnetworkpharmacologyandexperimentalvalidation
AT zhoubaofeng therapeuticeffectsofretinoicacidinlipopolysaccharideinducedcardiacdysfunctionnetworkpharmacologyandexperimentalvalidation
AT gengwujun therapeuticeffectsofretinoicacidinlipopolysaccharideinducedcardiacdysfunctionnetworkpharmacologyandexperimentalvalidation
AT tanghongli therapeuticeffectsofretinoicacidinlipopolysaccharideinducedcardiacdysfunctionnetworkpharmacologyandexperimentalvalidation